Xeris launches Ph2 trial of ready-to-use liquid glucagon

Xeris Pharmaceuticals - updatedXeris Pharmaceuticals (NSDQ:XERS) said today that it dosed the first patients in a Phase II trial of its ready-to-use liquid glucagon in people with Type 1 diabetes.

The Chicago-based company expects to report top-line data from the study in the second half of 2019.

Get the full story at our sister site, Drug Delivery Business News.

The post Xeris launches Ph2 trial of ready-to-use liquid glucagon appeared first on MassDevice.

Xeris Pharmaceuticals touts data for glucagon auto-injector

Xeris Pharmaceuticals - updatedXeris Pharmaceuticals (NSDQ:XERS) touted data this month for its ready-to-use glucagon auto-injector, highlighting the device’s efficacy and usability.

The Chicago-based company’s rescue pen is under review for approval by the FDA as a treatment for severe hypoglycemia in people with diabetes.

Get the full story at our sister site, Drug Delivery Business News.

The post Xeris Pharmaceuticals touts data for glucagon auto-injector appeared first on MassDevice.

FDA to review Xeris’ glucagon rescue pen auto-injector

Xeris Pharmaceuticals - updatedXeris Pharmaceuticals (NSDQ:XERS) said today that the FDA accepted its new drug application for a ready-to-use liquid glucagon rescue pen device.

The company’s product is designed to treat severe hypoglycemia in people with diabetes. The FDA is slated to make a decision about Xeris’ pen by June 10, 2019.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA to review Xeris’ glucagon rescue pen auto-injector appeared first on MassDevice.